Targeting Non-Mutant EGFR: Genetic and Clinical Biomarkers May Help Validate Use of Inhibitors
A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.
